Please assess the completion status of the following clinical trial:

Trial Title: UARK 2003-25: A Study of Intravenous (IV) Busulfan (Busulfex®) in Multiple Myeloma Patients

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients must have symptomatic multiple myeloma requiring treatment~* Patients must have been approved for single or tandem autologous transplant~* Patients must be \> or = 65 years of age or diagnosed with renal insufficiency, defined as having a creatinine \> 3 mg/dl or a creatinine clearance \< 30 ml/minute~* Patients must not have a history of chronic obstructive or chronic restrictive pulmonary disease. Patients must have adequate pulmonary function studies \> 50% of predicted on mechanical aspects (FEV1, FVC, etc) and diffusion capacity (DLCO) \> 50% of predicted,~* Patients must have an ECHO or MUGA performed within 60 days prior to registration, LVEF \> 40%.~* Bilirubin, SGOT, SGPT must be less than 1.5 times the upper limit of normal~* Patients must have evaluable myeloma marker for response such as: \*Serum M protein \>1g/dl or urine M protein \>1g/24 hours and/or; \*Bone marrow plasmacytosis with \>20% plasma cells and/or; \*Extramedullary plasmacytosis; \*MRI/PET scan has focal lesions due to myeloma.~* Patients must be able to receive full doses of DT-PACE, in the opinion of the treating investigator, with the exception of cisplatin.~* Patients must have a performance status of 0-2 based on SWOG criteria unless the patient's status is due to active myeloma~* All patients must be informed of the investigational nature of the study and have signed an IRB-approved informed consent in accordance with institutional and federal guidelines.~Exclusion Criteria:~* Serum transaminases \> 1.5 x ULN and direct bilirubin \> 1.5 mg/dl~* HIV positive or active Hepatitis B or Hepatitis C infection; (if serology is positive a quantitative PCR will be done).~* Patients with a prior malignancy in whom life expectancy is more likely to be determined by the prior malignancy than the myeloma. Patients must not currently be receiving therapy for the prior malignancy.~* Pregnant or nursing women. Women of childbearing potential must have a negative pregnancy test documented within one week of registration. Women/men of reproductive potential may not participate unless they have agreed to use an effective contraceptive method.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Busulfan (Type: EXPERIMENTAL): study-specific treatment: Busulfex according to study design: Level I 3.2 mg/kg over 6 hours x 2 days Level II 3.2 mg/kg over 6 hours x 3 days Level III 3.2 mg/kg over 6 hours x 4 days Level IV 4.3 mg/kg over 6 hours x 3 days Level V 5.6 mg/kg over 6 hours x 2 days Level VI 6.4 mg/kg over 6 hours x 2 days

Based on this trial design, predict the completion outcome and termination type (if applicable).